Health utility of patients with advanced gastrointestinal stromal tumors (GIST) after failure of imatinib and sunitinib: findings from GRID, a randomized, double-blind, placebo-controlled phase III study of regorafenib versus placebo.
about
Targeting gastrointestinal stromal tumors: the role of regorafenibEfficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access ProgramCost Effectiveness of Universal Hepatitis B Virus Screening in Patients Beginning Chemotherapy for Sarcomas or GI Stromal Tumors.Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program.Cost-Effectiveness Analysis of Regorafenib for Gastrointestinal Stromal Tumour (GIST) in Germany.Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors for Patients with Advanced Gastrointestinal Stromal Tumors.The safety of regorafenib for the treatment of gastrointestinal stromal tumors.
P2860
Q26747162-2A1A73CE-C6FA-4CF9-93CF-C7F07555E7F9Q33584090-2D1BBE4C-6729-47B8-B4F4-DBCC9EC679E7Q33872813-3ACED2DA-DB0E-47CB-A26E-6CAE118BC3CFQ35519994-22CBDEF0-A8A1-44BB-B974-04ADB0FD3E5DQ38865460-82D00162-F71A-4F8E-9E5F-76B2D8BEF530Q40567012-384AD18C-9589-4D56-A258-D7123CBBC8DAQ53805901-EEB5AA12-AC81-4787-8F66-92E73A688E6C
P2860
Health utility of patients with advanced gastrointestinal stromal tumors (GIST) after failure of imatinib and sunitinib: findings from GRID, a randomized, double-blind, placebo-controlled phase III study of regorafenib versus placebo.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Health utility of patients wit ...... of regorafenib versus placebo.
@ast
Health utility of patients wit ...... of regorafenib versus placebo.
@en
type
label
Health utility of patients wit ...... of regorafenib versus placebo.
@ast
Health utility of patients wit ...... of regorafenib versus placebo.
@en
prefLabel
Health utility of patients wit ...... of regorafenib versus placebo.
@ast
Health utility of patients wit ...... of regorafenib versus placebo.
@en
P2093
P2860
P1433
P1476
Health utility of patients wit ...... of regorafenib versus placebo.
@en
P2093
Chris D Poole
Craig J Currie
Jane Chang
Mark P Connolly
P2860
P2888
P304
P356
10.1007/S10120-014-0391-X
P577
2014-06-24T00:00:00Z